Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy
(COMMIT) Study: A Randomized Phase III Study of
mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single
Agent Atezolizumab in the First-Line Treatment of Patients with
Deficient DNA Mismatch Repair (dMMR)/Microsatellite
Instability-High (MSI-H) Metastatic Colorectal Cancer
Please contact us for more information or to learn if you are eligible to participate.
